# Dianthus Therapeutics, Inc. (DNTH)

> Source: Nexqual · https://nexqual.com/DNTH · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Dianthus Therapeutics, Inc. (DNTH), nexqual.com/DNTH" · informational, not investment advice.

**Price:** USD 74.53 (-0.31% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 74.76 · day 72.67–77.55 · 52w 32.22–117.88 · market cap $4.17B · NCM

## Key facts
- 1 of 80 tracked superinvestors hold DNTH (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 1.94 on a 1–5 scale) (17 analysts), mean target USD 140.8 (range 122–200).
- Total return with dividends: 1Y +107.0% vs S&P 500 +18.1%; 5Y -30.8% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.95, revenue estimate $366K.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold DNTH. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Polen Capital | Polen Capital Management | 0.01% | $910K | Added +126.6% |

## Analysts
Consensus Buy (mean 1.94 on a 1–5 scale), 17 analysts; mean target USD 140.8 (low 122, high 200).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | HC Wainwright & Co. | Reiterated | Buy | $158 |
| 2026-09-11 | JP Morgan | Initiated | Overweight | $135 |
| 2026-09-04 | Citigroup | Initiated | Buy | $156 |
| 2026-08-06 | Truist Securities | Target raised | Buy | $110 → $128 |
| 2026-08-06 | HC Wainwright & Co. | Target raised | Buy | $130 → $158 |
| 2026-08-05 | Wedbush | Target raised | Outperform | $105 → $122 |
| 2026-08-03 | Evercore ISI Group | Target raised | Outperform | $120 → $134 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +107.0% | -30.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +107.5% | -7.1% |
| Volatility (annualized) | 59.4% | 90.8% |
| Max drawdown | -35.7% (Aug 2026→Oct 2026) | -95.4% (Nov 2021→Dec 2022) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/DNTH · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt